ClinicalTrials.Veeva

Menu

A Prospective Cohort Study on Warfarin Personalized Medication

H

Haobin Li

Status

Completed

Conditions

Warfarin Sodium Causing Adverse Effects in Therapeutic Use

Study type

Observational

Funder types

Other

Identifiers

NCT06428110
2020081

Details and patient eligibility

About

Analyze the impact of the degree of blood vessel aging on the anticoagulant effect and bleeding risk of warfarin. Evaluating the possibility of using the degree of blood vessel aging to guide individualized use of the anticoagulant drug warfarin.

Enrollment

272 patients

Sex

All

Ages

65 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients aged 65 years and older, taking warfarin, with or without premature vascular aging, regardless of gender.

    • Patients who have not concurrently or intermittently used anticoagulant drugs, including antiplatelet drugs, heparin, low molecular weight heparin, and non-vitamin K-dependent oral anticoagulants, such as dabigatran and apixaban.

      • Signing an informed consent form before blood sample collection.

Exclusion criteria

  • Patients who are allergic to warfarin or lactose.

    • Patients who are receiving immunosuppressive agents or low molecular weight heparin anticoagulants.

      • Patients with bleeding tendencies, blood disorders with platelet counts > 400 × 10^9 /L or < 100 × 10^9 /L, hemoglobin > 169 or < 100 g/L.

        • History of peptic ulcer disease.

          • Malignant tumors, severe multi-organ dysfunction or failure such as heart, liver, and kidney.

            • Neurological disorders such as epilepsy.

Trial design

272 participants in 2 patient groups

Patients taking warfarin with vascular aging group
Patients taking warfarin with normal vascular group

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems